MedTrace Logo

Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy

NCT05406206 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2022-06-06

No results posted yet for this study

Summary

Fruquintinib (HMPL-013) is a novel oral small molecule that selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 and has demonstrated potent inhibitory effects on multiple human tumor xenografts. Combined with hepatic arterial infusion chemotherapy (HAIC), this study is conducted to assess the efficacy and safety of this regimen in patients with unresectable colorectal cancer liver metastases as the third-line therapy.

Conditions

  • Advanced Colorectal Carcinoma
  • Liver Metastasis Colon Cancer

Interventions

DRUG

Fruquintinib

Fruquintinib is a capsule in the form of 1mg and 5mg, once a day, 3 week on/1 week off.

PROCEDURE

Hepatic Arterial Infusion Chemotherapy

HAIC is a locoregional therapy for colorectal cancer liver metastasis. Oxaliplatin 85 mg/m\*2 + 5-FU 2000 mg/m\*2, Q4W

Sponsors & Collaborators

  • Peking University Cancer Hospital & Institute

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-25
Primary Completion
2023-07-31
Completion
2024-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05406206 on ClinicalTrials.gov